[Federal Register Volume 64, Number 100 (Tuesday, May 25, 1999)]
[Notices]
[Page 28214]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-13097]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importation of Controlled Substances; Notice of Application
Pursuant to section 1008 of the Controlled Substance Import and
Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to
issuing a regulation under this Section to a bulk manufacturer of a
controlled substance in Schedule I or II and prior to issuing a
regulation under section 1002(a) authorizing the importation of such a
substance, provide manufacturers holding registrations for the bulk
manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Sec. 1301.34 of Title 21, Code of
Federal Regulations (CFR), notice is hereby given that on March 2,
1999, Research Biochemicals, Limited Partnership, 1-3 Strathmore Road,
Natick, Massachusetts 01760, made application by renewal to the Drug
Enforcement Administration to be registered as an importer of the basic
classes of controlled substances listed below:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Methcathinone (1237)....................... I
Aminorex (1585)............................ I
Methaqualone (2565)........................ I
Alpha-Ethyltryptamine (7249)............... I
Ibogaine (7260)............................ I
Lysergic acid diethylamide (7315).......... I
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
Mescaline (7381)........................... I
Bufotenine (7433).......................... I
Etonitazene (9624)......................... I
Methylphenidate (1724)..................... II
Secobarbital (2315)........................ II
Glutethimide (2550)........................ II
Diprenorphine (9058)....................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Diphenoxylate (9170)....................... II
Hydrocodone (9193)......................... II
Levomethorphan (9210)...................... II
Levorphanol (9220)......................... II
Meperidine (9230).......................... II
Metazocine (9240).......................... II
Methadone (9250)........................... II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Thebaine (9333)............................ II
Levo-alphacetylmethadol (LAAM) (9648)...... II
Oxymorphone (9652)......................... II
------------------------------------------------------------------------
The firm plans to import small quantities of the listed controlled
substances to manufacture laboratory reference standards and
neurochemicals.
Any manufacturer holding, or applying for, registration as a bulk
manufacturer of these basic classes of controlled substances may file
written comments on or objections to the application described above
and may, at the same time, file a written request for a hearing on such
application in accordance with 21 CFR 1301.43 in such form as
prescribed by 21 CFR 1316.47. Any such comments, objections, or
requests for a hearing may be addressed, in quintuplicate, to the
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration, United States Department of Justice,
Washington, DC 20537, Attention: DEA Federal Register Representative
(CCR), and must be filed no later than (30 days from publication).
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b), (c), (d),
(e), and (f). As noted in a previous notice at 40 FR 43745-46
(September 23, 1975), all applicants for registration to import the
basic classes of any controlled substances in Schedule I or II are and
will continue to be required to demonstrate to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration that the requirements for such registration pursuant to
21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(a), (b), (c),
(d), (e), and (f) are satisfied.
Dated: May 14, 1999.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 99-13097 Filed 5-24-99; 8:45 am]
BILLING CODE 4410-09-M
